Skin, Hair & Glow · commonly explored around skin and hair
PT-141 (Bremelanotide)
PT-141, or bremelanotide, works on desire signals in the brain rather than blood flow. A prescription form, Vyleesi, is approved for low sexual desire in some premenopausal women.
Informational profile
No verified OnimaChain inventory for this profile.
Also known as Bremelanotide · Vyleesi
Mapped targets
- Sequence
- XDHFRWK
- Length
- 7 residues
- MW
- 1025.18 Da computed
- Product tags
- melanocortin · cyclic lactam · d residue
- Checked sources
- No checked source added yet
- Structure provenance
- Sequence-derived illustration (not a measured structure)
Bremelanotide has a free-acid C terminus; Melanotan II has an amide there. Source: FDA Vyleesi chemistry review (NDA 210557).
See the simple guide ↓Video intro
PT-141 (Bremelanotide) in ten seconds.
Coming soon.
Meet PT-141 (Bremelanotide)
The short version, before the deep dive.
PT-141, or bremelanotide, works on desire signals in the brain rather than blood flow. A prescription form, Vyleesi, is approved for low sexual desire in some premenopausal women.
PulseChain
What’s new with PT-141 (Bremelanotide)
Section B
The quick read
Section C
Research at a glance
A simple picture of the sources we have checked. More color means more records in that category—not that the product works better.
We haven’t added a checked source for this yet.
This picture fills in as we add checked studies for this product.
Section D
What the sources looked at
These topics come only from sources in our record. We do not add a topic just because it is popular online.
No topics yet
Topics show up here once we have checked studies for this product and sorted them.
Section E
Why people look it up
A plain-language starting point. This is not a promise that the product will cause a result.
skin and hair
See PT-141 (Bremelanotide) beside similar names.
The Portal of Tides lets you switch between a constellation, connection view, checked-source timeline, and topic map. It uses the products already in our collection—no fake customer counts.
Section F
What the record can tell us
A product page can show what was studied. It cannot promise what will happen to a person.
What we can show
No source topic has been added yet.
What we cannot promise
A lab result, animal study, online story, or product page cannot tell you what will happen to you. That question needs qualified medical guidance.
Section G
Claims people make
The big claims tied to this product. Open one to see where it came from and how it spread.
No claims tracked for this product yet
We only add a claim once we can point to where it started, or say clearly that we could not find out.
Section H
How far it has been tested
From cells in a dish, to mice, rats, bigger animals, people, proper trials, and finally regulator approval. The light stops where the checked studies stop.
We have not mapped how far any result has been tested yet.
Section I
How many separate teams
Ten papers from one lab are not ten separate confirmations.
Not checked yet
We only count teams from studies we have confirmed.
Section J
What doesn’t fit?
If a study disagrees, it goes here. We do not hide it.
No study we have checked pushes back yet
Studies that found nothing, disagree, or criticize the method will show up here once we add them. A study that only partly agrees is not the same as one that disagrees.
Section K
Timeline
What happened and when. Studies in one lane, real-world reports in another.
Research
0 events
No dated research update is indexed for this selection.
Trials
0 events
No trial milestones are indexed to this exact record yet.
Regulatory
0 events
No regulator decisions listed yet.
Real-world reports
0 events
No real-world reports yet — social platforms are not connected.
Section L
Sources
Every study we used. Only studies we confirmed on PubMed are shown as sources. Where a drug is FDA-approved, its official label sits beside them — that is an approval, not a sales pitch.
FDA application
Vyleesi (bremelanotide) — Drugs@FDA application overview
NDA 210557 · retrieved 2026-09-21
FDA-approved (2019) as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Not approved as a general sexual-performance product. The label excludes use when low desire is due to a co-existing medical or psychiatric condition, relationship problem, or substance.
Open source ↗DailyMed index
Vyleesi (bremelanotide) — DailyMed label index
DailyMed query VYLEESI · retrieved 2026-09-21
VYLEESI (bremelanotide injection), for subcutaneous use. Initial U.S. approval: 2019. Contraindicated in uncontrolled hypertension or known cardiovascular disease.
Open source ↗We have not added PubMed studies for this product yet. The official labels above are the sources for now.
The building blocks, one by one
| # | Code | Residue | Class | Chirality | Features |
|---|---|---|---|---|---|
| 1 | Nle | Norleucine | hydrophobic | L | Non-standard residueN-acetyl cap |
| 2 | D | Aspartate | negative | L | |
| 3 | H | Histidine | positive | L | |
| 4 | F | Phenylalanine | hydrophobic | D | D-residue |
| 5 | R | Arginine | positive | L | |
| 6 | W | Tryptophan | hydrophobic | L | |
| 7 | K | Lysine | positive | L |